+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Trends in alpha-blocker treatment of patients with benign prostatic hyperplasia and hypertension: Dosing regimens and cost comparisons

Trends in alpha-blocker treatment of patients with benign prostatic hyperplasia and hypertension: Dosing regimens and cost comparisons

Clinical Therapeutics 19(4): 821-829

Dosing regimen is an important determinant of both drug cost and patient compliance. This retrospective analysis evaluated dosing regimens and drug acquisition costs for 101 patients identified from medical records in a large metropolitan hospital as having hypertension and/or benign prostatic hyperplasia and receiving alpha-blocker therapy with either doxazosin or terazosin. Although once-daily administration is generally recommended for both drugs, 25 (38%) of 66 patients receiving terazosin were treated twice daily compared with 6 (17%) of 35 patients treated twice daily with doxazosin. This difference was statistically significant. The average (mean +/- SD) daily treatment cost per patient for all individuals receiving terazosin during the period of the record review was $1.68 +/- 0.60. For patients treated with doxazosin, the average was $0.96 +/- 0.65-a highly statistically significant result. If all 66 patients receiving terazosin had been converted to doxazosin at the beginning of the study, annual savings would have been $17,345.00. These results demonstrate the importance of reviewing actual dosing regimens. The fact that doxazosin could be administered to a significantly higher percentage of patients once daily rather than twice daily substantially decreased its cost relative to terazosin. A once-daily treatment regimen may also enhance patient compliance, thereby improving the chances of therapeutic success.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 009675309

Download citation: RISBibTeXText

PMID: 9377624

DOI: 10.1016/s0149-2918(97)80105-1

Related references

Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia. Korean Journal of Urology 53(2): 92-97, 2012

The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin. Terapevticheskii Arkhiv 69(10): 79-82, 1997

The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia. Urology 88: 149-154, 2016

α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results. Korean Journal of Urology 53(4): 248-252, 2012

Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data. Advances in Therapy 35(8): 1191-1198, 2018

Clinical and urodynamic results of alpha-blocker drug treatment in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Archivos Espanoles de Urologia 68(2): 161-171, 2016

Effects of short-term treatment with the alpha-1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. European Urology 32(1): 47-53, 1997

Study of patients with symptomatic benign prostatic hyperplasia who underwent transurethral resection of the prostate after ineffective alpha-1 blocker treatment by non-urologists. Hinyokika Kiyo. Acta Urologica Japonica 52(2): 95-98, 2006

Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. Journal of Medical Economics 15(3): 586-600, 2012

Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. Journal of Urology 161(1): 139-143, 1999

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia. Bmc Urology 17(1): 83, 2018

Treatment patterns in alpha-blocker therapy for benign prostatic hyperplasia. American Journal of Men's Health 8(3): 267-272, 2014

Apoptotic and proliferative index after alpha-blocker and/or finasteride treatment in benign prostatic hyperplasia. Journal of Urology 165(5 Supplement): 213, 2001

Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. International Urology and Nephrology 42(1): 7-12, 2010

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. Plos One 12(1): E0169248, 2017